Palovarotene is under clinical development by Ipsen and currently in the Phase I and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Palovarotene’s likelihood of approval (LoA) and phase transition for Keratoconjunctivitis Sicca (Dry Eye) took place on 27 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Palovarotene Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Palovarotene overview

Palovarotene (Sohonos) is a member of the retinoid class of drugs that is associated with birth defects in humans. It is formulated as capsules for oral administration. Sohonos is indicated to reduce the formation of heterotopic ossification in adults and children aged 8 years and above for females and 10 years and above for males with Fibrodysplasia (myositis) Ossificans Progressiva.

Ipsen overview

Ipsen is a global specialty biopharmaceutical company engaged in the manufacturing and distribution of drugs for the treatment of cancer, rare diseases and neurological diseases, including specialty pharmaceutical products. The company develops and commercializes novel medicines for cancer, neuroscience and rare diseases and also offers products to treat gastrointestinal disorders, neurodegenerative pathologies and rheumatic diseases. Ipsen sells its drugs through a network of distributors and directly to hospitals in a few countries. The company operates its research and development facilities in Paris-Saclay, France; Oxford, the UK; and Cambridge, the US. The company offers products in Europe, North America, Asia and rest of the world. Ipsen is headquartered in Paris, France.

Quick View Palovarotene LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Palovarotene
Administration Pathway
  • Ophthalmic
  • Oral
Therapeutic Areas
  • Musculoskeletal Disorders
  • Ophthalmology
  • Respiratory
Key Developers
  • Sponsor Company: Ipsen
  • Originator: F. Hoffmann-La Roche
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.